Elizabeth A. Keegan
Senior Counsel
Overview
An accomplished transactional lawyer, Liz Keegan advises life sciences companies engaged in drug, cell therapy, gene therapy, and medical device research and development with academic institutions, industry collaborators, and service providers.
Career & Education
- Corporate Associate, AmLaw 50 firm
- Represented clients across a wide range of industries with matters pertaining to public and private mergers, stock and asset sales, the registration and sale of equity securities, securities law compliance, and corporate governance matters.
- Legal Intern, Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)
- Corporate Associate, AmLaw 50 firm
- Colby College, B.A.
- Northeastern University School of Law, J.D.
- California
- Massachusetts
Representative Matters
Licensing and Collaboration Agreements
- Represented an early-stage client in an exclusive Patent License Agreement and Research Collaboration Agreement with a notable Boston research hospital for the transfer of intellectual property rights for the development of adeno-associated virus (AAV) and gene-based therapies for the treatment of a rare genetic disease.
- Represented a public biopharmaceutical company in a Research Collaboration Agreement with a renowned cancer center for funding of CAR T-cell therapy research.
- Represented a clinical-stage, global, biopharmaceutical company in a Sponsored Research Agreement with a prominent DC university to research the activity of the client’s compound.
Manufacturing and Clinical Development Agreements
- Represented a clinical-stage subsidiary of a commercial-stage biopharmaceutical company in the negotiation of a complex development and manufacturing agreement with a strategic partner for clinical supply of BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for Canavan disease.
- Advised a clinical-stage biotechnology company focused on developing and commercializing precision oncology medicines in the negotiation of a development and manufacturing agreement with a European CMO for the development and clinical supply of capsule formulation.
- Advised in the development and implementation of a suite of U.S. and ex-U.S. clinical trial-related agreement templates in support of a global, multicenter, Phase 2 study of a therapeutic for the treatment of HR-positive/HER2-negative metastatic breast cancer.
- Drafted and negotiated various multi-million-dollar master services agreements with global contract research organizations for large, multinational clinical studies of therapeutic and medical device products.